Finasteride is a synthetic 5-alpha reductase inhibitor primarily used in the management of androgen-dependent conditions such as androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH). It is not an endogenous hormone but a pharmaceutical compound developed to interfere with specific androgen pathways. Finasteride belongs to the chemical class of azasteroids and is produced synthetically for therapeutic use. Researchers have extensively studied finasteride for its role in reducing dihydrotestosterone (DHT) levels, a potent androgen involved in hair loss and prostate enlargement. The primary physiological role of finasteride is to inhibit the conversion of testosterone to DHT, thereby mitigating conditions like AGA and BPH. Research has focused on its efficacy in increasing hair count and reducing prostate size, with particular interest in its side effect profile. Finasteride acts by selectively inhibiting the type II isoenzyme of 5-alpha reductase, which is responsible for the conversion of testosterone to DHT. This inhibition leads to a decrease in DHT levels, particularly in tissues like the scalp and prostate, thereby reducing the progression of androgen-dependent conditions. The pharmacokinetic properties of finasteride include an oral bioavailability with a plasma half-life of approximately 4.5 hours. It is metabolized primarily in the liver and excreted in urine and feces. The drug's systemic exposure is significantly reduced when applied topically, minimizing potential systemic side effects. Clinically, finasteride is approved for use in male pattern baldness and BPH. In the United States, it is available as Propecia (1 mg) for AGA and Proscar (5 mg) for BPH. Regulatory bodies in various countries have approved its use, although it is associated with side effects such as sexual dysfunction and potential psychiatric effects, necessitating careful patient education and monitoring.